Trial: 202009092

A TWO-PART, PHASE 1A/B, OPEN-LABEL, MULTICENTER TRIAL
EVALUATING PHARMACOKINETICS, SAFETY AND EFFICACY OF
PF-07284890 (ARRY-461) IN PARTICIPANTS WITH BRAF V600-MUTANT SOLID
TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT

Phase

I

Principal Investigator

Ansstas, George

Disease Site

Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Lung Cancer – Non-small Cell; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Urinary Bladder

Learn more about this study at: clinicaltrials.gov